Christian Rausch
Overview
Explore the profile of Christian Rausch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1576
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Archer K, Fu H, Mrozek K, Nicolet D, Mims A, Uy G, et al.
Innovation (Camb)
. 2024 Nov;
5(6):100719.
PMID: 39529956
Assignment of patients diagnosed with acute myeloid leukemia (AML) to the 2022 European LeukemiaNet (ELN) favorable genetic risk group has important clinical implications, as allogeneic stem cell transplantation in first...
2.
Rausch C, Arnreich C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, et al.
Dtsch Arztebl Int
. 2024 Mar;
121(3):94-95.
PMID: 38471183
No abstract available.
3.
Thaci D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, et al.
Br J Dermatol
. 2023 Dec;
191(1):36-48.
PMID: 38133615
Background: The anti-interleukin-23 antibody guselkumab (GUS) demonstrated favourable week 24 efficacy and safety over fumaric acid esters (FAE) in systemic treatment-naïve patients with moderate-to-severe plaque psoriasis (study part I). Objectives:...
4.
Wang D, Rausch C, Buerger S, Tschuri S, Rothenberg-Thurley M, Schulz M, et al.
iScience
. 2023 Dec;
26(12):108271.
PMID: 38047080
Monitoring disease response after intensive chemotherapy for acute myeloid leukemia (AML) currently requires invasive bone marrow biopsies, imposing a significant burden on patients. In contrast, cell-free tumor DNA (ctDNA) in...
5.
Mo M, Thiesmeier R, Kiwango G, Rausch C, Moller J, Liang Y
J Cardiovasc Dev Dis
. 2023 Oct;
10(10).
PMID: 37887873
Background: There is limited evidence on the effect of low birthweight on the use of cardiovascular medications and the role of health behaviors. This study aims to determine the independent...
6.
Eckardt J, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, et al.
Leukemia
. 2023 Sep;
37(11):2282-2285.
PMID: 37679502
No abstract available.
7.
Rausch C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, Sauerland C, et al.
Leukemia
. 2023 Apr;
37(6):1234-1244.
PMID: 37041198
The revised 2022 European LeukemiaNet (ELN) AML risk stratification system requires validation in large, homogeneously treated cohorts. We studied 1118 newly diagnosed AML patients (median age, 58 years; range, 18-86...
8.
van Wagensveld L, van Baal J, Timmermans M, Gaillard D, Borghuis L, Coffelt S, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497449
Background: How molecular profiles are associated with tumor microenvironment (TME) in high-grade serous ovarian cancer (HGSOC) is incompletely understood. Therefore, we analyzed the TME and molecular profiles of HGSOC and...
9.
van der Vlugt M, Carvalho B, Fliers J, Montazeri N, Rausch C, Grobbee E, et al.
World J Gastrointest Oncol
. 2022 Nov;
14(11):2195-2207.
PMID: 36438700
Background: For optimizing fecal immunochemical test (FIT)-based screening programs, reducing the rate of missed colorectal cancers (CRCs) by FIT (FIT-interval CRCs) is an important aspect. Knowledge of the molecular make-up...
10.
Wirth A, Wange L, Vosberg S, Henrich K, Rausch C, Ozdemir E, et al.
Leukemia
. 2022 Nov;
36(12):2863-2874.
PMID: 36333584
Resistance towards cancer treatment represents a major clinical obstacle, preventing cure of cancer patients. To gain mechanistic insights, we developed a model for acquired resistance to chemotherapy by treating mice...